top of page


Why the EU’s Antibiotic Revenue Guarantee Scheme Stalled – and how to fix it
Bringing life-saving antibiotics to market is a paradox: doctors depend on them, yet are trained to use them sparingly. This creates a...

David McKinney
Mar 275 min read


The EU's Leading Role on Supporting Antimicrobial R&D and Access
Antimicrobial therapeutics have extremely high societal value and investing in a strong R&D ecosystem and market offers an opportunity to...

ARMoR
Dec 10, 20241 min read


Taking Action on Pull Incentives in Sweden
Key Messages: Antimicrobial Resistance is a growing health concern, both across the globe where it is attributed with 1.27 million deaths...

Aanika Dalal
Sep 16, 20242 min read


Strengthening National Action Plans for AMR: The Case for Commitments to Pull Incentives
Antimicrobial resistance (AMR) is a severe global health threat. In the EU alone, there were an estimated 58,300 fatalities directly...

ARMoR
Aug 14, 20245 min read


Tackling the antimicrobial Research and Development and access crisis: An overview
This is a cross-post from a guest article written for the European Public Health Alliance . The importance of antimicrobial medicines in...

David McKinney
Jul 23, 20244 min read


Estimating the Return on Investment of Pull Incentive Policies for New Antimicrobials: Insights for the EU and Beyond
Key Messages:Â Antimicrobial resistance is an increasing global threat and the world needs a reliable pipeline of new, effective...

Aanika Dalal
Jul 15, 20241 min read


Taking Action on Pull Incentives: Estimating the Return on Investment for Incentivising New Antimicrobials in Denmark
Key Messages: Antimicrobial Resistance is a growing health concern, both globally and in Denmark, and is associated with an estimated...

ARMoR
May 2, 20241 min read
bottom of page